Objective: This study was designed to assess the apolipoprotein B (Apo-B), apolipoprotein A (Apo A) and Apo B/Apo A-I ratio in subjects with and
withoutmetabolic syndrome andtoevaluate the correlationofApoB/ApoA-Iratiowithoxidative stressmarker andcardiovasculardisease risk.
Methods:Atotal of 308 subjects including one hundred and fty- ve cases and one hundred and fty- three controls were recruited for this study.
All the subjects were classied according to the NCEPATP III (National cholesterol education program – Adult treatment panel III) criteria for
MetS. Anthropometric and clinical characteristics were recorded using clinical Proforma. Blood samples were collected for doing plasma glucose,
Lipid prole analysis [Total Cholesterol (TC), Triglyceride (TG), high-density lipoprotein (HDL)], ApoA1, Apo B and oxidative stress marker -
Malondialdehyde (MDA). Serum low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and Apo B/Apo A-I ratio were calculated.
Comparison of data between the two groups was done by t test. Correlation coefcient of Apo B/ Apo A1 ratio with cadiometabolic risk factors were
calculated.
Result: We found that cardiometabolic risk factors like abdominal obesity, systolic and diastolic blood pressure, fasting plasma glucose, TG,
atherogenic lipoproteins LDL, Apo B, Apo B/Apo A-I ratio and MDA were signicantly high in subjects with MetS whereas anti-atherogenic
factor Apo A1 was signicantly low. We also observed that Apo B/AI ratio was positively related to cardiometabolic risk factors and with oxidative
stress marker.
Conclusion:Apo B/AI ratio was related to metabolic syndrome and was found to be a reliable indicator of cardiovascular risk in MetS.